Pharma RSS Digest - 2026-07-16

Overview

Today's pharma tape is anchored by a high-impact Phase III readout from Kelun-Biotech — the first ADC plus checkpoint inhibitor combination to hit its primary endpoint in first-line PD-L1-negative non-squamous NSCLC — alongside a state-level regulatory clearance for Castle Biosciences' atopic dermatitis companion diagnostic. Clinical momentum is reinforced by Lynk Pharmaceuticals completing enrollment in a JAK1 inhibitor ankylosing spondylitis Phase III. Outside of substantive R&D news, QuidelOrtho filed a routine inducement grant to its incoming CFO, which is a governance formality rather than a strategic catalyst. The overall signal is constructive for oncology and inflammation pipelines, with one notable executive-completion paperwork filing mixed in.

Key Developments

Castle Biosciences received New York State Department of Health approval for its AdvanceAD-Tx test on July 14, 2026, a non-invasive gene expression profile assay intended to guide systemic therapy selection in patients aged 12 and older with moderate-to-severe atopic dermatitis. New York is the only U.S. state requiring formal pre-market review of laboratory-developed tests, so this clearance effectively completes Castle's nationwide commercial rollout and validates the test against the country's most rigorous LDT review. The approval also brings Castle full NY coverage across its dermatology, ophthalmology, and TissueCypher gastroenterology franchises. What to watch next: payer coverage decisions in New York, real-world adoption of the JAK Inhibitor Responder and Th2 Molecular profiles, and any peer-reviewed publication of the validation data.

Castle Biosciences fda approval update

Kelun-Biotech's sacituzumab tirumotecan (sac-TMT) plus pembrolizumab hit the primary PFS endpoint at a pre-specified interim of the Phase III OptiTROP-Lung06 trial in first-line PD-L1-negative (TPS <1%) non-squamous NSCLC, with a positive but unconfirmed overall survival trend and no new safety signals. The head-to-head design against pembrolizumab plus pemetrexed/platinum chemo is described by the company as the first Phase III of an ADC plus checkpoint inhibitor to succeed in driver-gene-negative, PD-L1-negative NSCLC, a setting with limited options today. Combined with the parallel OptiTROP-Lung05 readout in PD-L1-positive disease, sac-TMT now has a positioning story that could span the full first-line non-squamous NSCLC population. What to watch next: detailed subgroup and OS data, a formal CDE/NMPA filing path, and the FDA pathway via MSD/Merck.

QuidelOrtho fda approval update

Lynk Pharmaceuticals completed enrollment of 352 patients in its Phase III trial of the second-generation selective JAK1 inhibitor zemprocitinib in active ankylosing spondylitis, with a Week 16 ASAS40 primary endpoint and treatment/follow-up ongoing. Prior Phase III data in rheumatoid arthritis (24-week) and atopic dermatitis (52-week) already met their primary and key secondary endpoints, lending cross-indication credibility. As an oral JAK1 therapy, zemprocitinib is positioned to compete in an AS market dominated by NSAIDs and biologics with documented unmet need. What to watch next: topline efficacy and safety readouts, regulatory filing timelines, and head-to-head differentiation versus approved JAK inhibitors and biologics.

Kelun-Biotech clinical trial update

QuidelOrtho disclosed an inducement grant of 356,555 RSUs to incoming CFO Micah Young, approved by the Compensation Committee on July 15, 2026 under the company's 2026 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The award vests in three equal annual installments and formalizes Mr. Young's onboarding following his previously announced CFO appointment. This is a routine executive-compensation filing rather than a substantive corporate or pipeline catalyst, but it does give investors visibility into long-term incentive commitments tied to the new finance leadership. What to watch next: any disclosure of base salary, bonus structure, or termination provisions, and the timing of Mr. Young's first earnings cycle as CFO.

Lynk Pharmaceuticals clinical trial update

Watchlist

• Vanda Pharmaceuticals announced its motion-sickness drug NEREUS (tradipitant) will sponsor the No. 47 IndyCar entry in the 2026 NTT IndyCar Series, positioning it as the first new U.S. prescription motion-sickness treatment in roughly 47 years — a brand-awareness play rather than a clinical catalyst. [link]
• Leica Biosystems (a Danaher operating company) signed a definitive agreement to acquire private anatomical pathology products maker StatLab from Linden Capital Partners and Audax Private Equity, expected to close by year-end 2026; financial terms were not disclosed. [link]
• Universal Health Services declared a $0.20 per share cash dividend payable September 15, 2026 to shareholders of record September 1, 2026, confirming continued capital return discipline at one of the largest U.S. hospital and behavioral health operators. [link]